Advances in the vaccination of the elderly against influenza

Role of a high-dose vaccine

Seth J. Sullivan, Robert Jacobson, Gregory A. Poland

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

On 23 December 2009, the US FDA approved Fluzone® High Dose, a high-dose formulation of the trivalent inactivated influenza vaccine, for prevention of influenza in people 65 years of age and older. As it was approved via an accelerated process designed to allow expeditious availability of safe and effective products with promise to treat or prevent serious or life-threatening diseases, the manufacturer is required to conduct further studies to demonstrate effectiveness. Although these studies are underway, a recently completed randomized, controlled trial demonstrated that this vaccine, containing four-times more hemagglutinin than standard-dose inactivated influenza vaccines, can produce an enhanced immunologic response in subjects of 65 years of age and older, while maintaining a favorable safety profile. This article introduces the vaccine, presents currently available safety and immunogenicity data, discusses current recommendations for use, and proposes what we can expect in the coming years.

Original languageEnglish (US)
Pages (from-to)1127-1133
Number of pages7
JournalExpert Review of Vaccines
Volume9
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

Inactivated Vaccines
Influenza Vaccines
Human Influenza
Vaccination
Vaccines
Safety
Hemagglutinins
Randomized Controlled Trials

Keywords

  • active immunization
  • aged
  • aging
  • human
  • immune system
  • immunization
  • immunosenescence
  • inactivated
  • influenza
  • influenza vaccine
  • vaccine
  • viral vaccine

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Advances in the vaccination of the elderly against influenza : Role of a high-dose vaccine. / Sullivan, Seth J.; Jacobson, Robert; Poland, Gregory A.

In: Expert Review of Vaccines, Vol. 9, No. 10, 10.2010, p. 1127-1133.

Research output: Contribution to journalArticle

Sullivan, Seth J. ; Jacobson, Robert ; Poland, Gregory A. / Advances in the vaccination of the elderly against influenza : Role of a high-dose vaccine. In: Expert Review of Vaccines. 2010 ; Vol. 9, No. 10. pp. 1127-1133.
@article{96a3646e49f743cc9ffe5faaa58287b1,
title = "Advances in the vaccination of the elderly against influenza: Role of a high-dose vaccine",
abstract = "On 23 December 2009, the US FDA approved Fluzone{\circledR} High Dose, a high-dose formulation of the trivalent inactivated influenza vaccine, for prevention of influenza in people 65 years of age and older. As it was approved via an accelerated process designed to allow expeditious availability of safe and effective products with promise to treat or prevent serious or life-threatening diseases, the manufacturer is required to conduct further studies to demonstrate effectiveness. Although these studies are underway, a recently completed randomized, controlled trial demonstrated that this vaccine, containing four-times more hemagglutinin than standard-dose inactivated influenza vaccines, can produce an enhanced immunologic response in subjects of 65 years of age and older, while maintaining a favorable safety profile. This article introduces the vaccine, presents currently available safety and immunogenicity data, discusses current recommendations for use, and proposes what we can expect in the coming years.",
keywords = "active immunization, aged, aging, human, immune system, immunization, immunosenescence, inactivated, influenza, influenza vaccine, vaccine, viral vaccine",
author = "Sullivan, {Seth J.} and Robert Jacobson and Poland, {Gregory A.}",
year = "2010",
month = "10",
doi = "10.1586/erv.10.117",
language = "English (US)",
volume = "9",
pages = "1127--1133",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Advances in the vaccination of the elderly against influenza

T2 - Role of a high-dose vaccine

AU - Sullivan, Seth J.

AU - Jacobson, Robert

AU - Poland, Gregory A.

PY - 2010/10

Y1 - 2010/10

N2 - On 23 December 2009, the US FDA approved Fluzone® High Dose, a high-dose formulation of the trivalent inactivated influenza vaccine, for prevention of influenza in people 65 years of age and older. As it was approved via an accelerated process designed to allow expeditious availability of safe and effective products with promise to treat or prevent serious or life-threatening diseases, the manufacturer is required to conduct further studies to demonstrate effectiveness. Although these studies are underway, a recently completed randomized, controlled trial demonstrated that this vaccine, containing four-times more hemagglutinin than standard-dose inactivated influenza vaccines, can produce an enhanced immunologic response in subjects of 65 years of age and older, while maintaining a favorable safety profile. This article introduces the vaccine, presents currently available safety and immunogenicity data, discusses current recommendations for use, and proposes what we can expect in the coming years.

AB - On 23 December 2009, the US FDA approved Fluzone® High Dose, a high-dose formulation of the trivalent inactivated influenza vaccine, for prevention of influenza in people 65 years of age and older. As it was approved via an accelerated process designed to allow expeditious availability of safe and effective products with promise to treat or prevent serious or life-threatening diseases, the manufacturer is required to conduct further studies to demonstrate effectiveness. Although these studies are underway, a recently completed randomized, controlled trial demonstrated that this vaccine, containing four-times more hemagglutinin than standard-dose inactivated influenza vaccines, can produce an enhanced immunologic response in subjects of 65 years of age and older, while maintaining a favorable safety profile. This article introduces the vaccine, presents currently available safety and immunogenicity data, discusses current recommendations for use, and proposes what we can expect in the coming years.

KW - active immunization

KW - aged

KW - aging

KW - human

KW - immune system

KW - immunization

KW - immunosenescence

KW - inactivated

KW - influenza

KW - influenza vaccine

KW - vaccine

KW - viral vaccine

UR - http://www.scopus.com/inward/record.url?scp=77957957218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957957218&partnerID=8YFLogxK

U2 - 10.1586/erv.10.117

DO - 10.1586/erv.10.117

M3 - Article

VL - 9

SP - 1127

EP - 1133

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 10

ER -